pg-545 has been researched along with Fatty-Liver* in 1 studies
1 other study(ies) available for pg-545 and Fatty-Liver
Article | Year |
---|---|
Heparanase inhibition attenuates atherosclerosis progression and liver steatosis in E
Increased oxidative stress is associated with accelerated atherosclerosis. Emerging evidence highlights the role of heparanase in atherogenesis, where heparanase inhibitor PG545 reduces oxidative stress in apolipoprotein E deficient mice (E. Blood pressure decreased in mice treated with low, but not high dose of PG545. In addition, heparanase inhibition caused a dose-dependent reduction in serum oxidative stress, total cholesterol, low-density lipoproteins, triglycerides, high-density lipoproteins, and aryl esterase activity. Although food intake was not reduced by PG545, body weight gain was significantly attenuated in PG545 treated groups. Both doses of PG545 caused a marked reduction in aortic wall thickness and atherosclerosis development, and liver steatosis. Liver enzymes and serum creatinine were not affected by PG545.. Heparanase inhibition by PG545 caused a significant reduction in lipid profile and serum oxidative stress along with attenuation of atherosclerosis, aortic wall thickness, and liver steatosis. Moreover, PG545 attenuated weight gain without reducing food intake. Collectively, these findings suggest that heparanase blockade is highly effective in slowing atherosclerosis formation and progression, and decreasing liver steatosis. Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Blood Pressure; Disease Models, Animal; Disease Progression; Fatty Liver; Glucuronidase; Glycoside Hydrolase Inhibitors; Lipids; Liver; Male; Mice, Knockout, ApoE; Oxidative Stress; Plaque, Atherosclerotic; Saponins | 2018 |